QNRX - Quoin Pharmaceuticals, Ltd. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

QNRX

QUOIN PHARMACEUTICALS, LTD.

NASDAQ

$6.12

▲ UP 18.72% (0.96)

KEY STATISTICS

Market Cap$12.29 M

52w High$41.80

52w Low$3.25

Dividend Yield—

Frequency—

P/E-0.21

Volume30.89M

Shares Out.2.01M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Michael Myers

COMPENSATION 2026

Salary$745,284

Stock Awards$0

Incentive Plan Pay$372,642

All Other Comp.$58,134

Total$1,507,345

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 1, 2016

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2023-07-18	Reverse	1:12
2022-08-01	Reverse	2:25
2021-09-24	Reverse	1:4
2019-10-23	Reverse	1:5

PRICE

$6.12 ▲ UP 18.72% (+$0.96)

OVERLAYS

About Quoin Pharmaceuticals, Ltd.

https://quoinpharma.com ↗

Quoin Pharmaceuticals, Ltd. develops therapies for rare diseases, including QRX003 for Netherton Syndrome, QRX004 for dystrophic epidermolysis bullosa, and QRX006 for rare skin conditions, based in Ashburn, Virginia.

INDUSTRY

Biotechnology

A PRODUCT QUOIN PHARMACEUTICALS, LTD. IS KNOWN FOR

QRX003

QRX003, developed by Quoin Pharmaceuticals, is a topical lotion in clinical trials for Netherton Syndrome, a rare genetic skin disorder, reflecting Quoin's focus on creating treatments for orphan diseases lacking approved therapies.